No Data
Flagship Pioneering Announces Two New Agreements With Ampersand Biomedicines and Montai Therapeutics Under Its Strategic Partnership With Pfizer
Foghorn Therapeutics (FHTX) Collaborates With Eli Lilly and Surpasses Q3 Expectations
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.
H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating
No Data
No Data